Health Care • Biotechnology: Pharmaceutical Preparations
$1.83 ▲ +0.04
(+2.24%)
MKT CAP: $21.2M • VOL: 4.3K
52W L $1 52W H $3
ROARABLE / RQD
D • 48/100
PIOTROSKI
2 / 9
TXMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $1.8M | $1.3M |
| YoY Revenue Growth % | — | +35.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$4.4M | -$6.1M | -$8.5M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$569.0K | -$2.2M | -$10.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | — | — | — |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | — | — | — |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -12.9% | -21.6% | — |
| Cash & Short-Term Equivalents | — | $5.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $26.9M | $27.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TXMD.